Literature DB >> 10493662

An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine.

M Easterbrook.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493662

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


× No keyword cloud information.
  6 in total

Review 1.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 2.  Ocular toxicity due to chloroquine and hydroxychloroquine: electrophysiological and visual function correlates.

Authors:  Radouil Tzekov
Journal:  Doc Ophthalmol       Date:  2005-01       Impact factor: 2.379

3.  ERG findings in patients using hydroxychloroquine.

Authors:  Radouil T Tzekov; Alexandra Serrato; Michael F Marmor
Journal:  Doc Ophthalmol       Date:  2004-01       Impact factor: 2.379

4.  Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case-control study with hydroxychloroquine blood-level analysis.

Authors:  Tiphaine Lenfant; Sawsen Salah; Gaëlle Leroux; Elodie Bousquet; Véronique Le Guern; François Chasset; Camille Francès; Nathalie Morel; Julie Chezel; Thomas Papo; Patrice Cacoub; Luc Mouthon; Gaëlle Guettrot-Imbert; Pascal Cohen; Alexis Régent; Martine Mauget-Faÿsse; Jean-Charles Piette; Moez Jallouli; Nathalie Costedoat-Chalumeau
Journal:  Rheumatology (Oxford)       Date:  2020-12-01       Impact factor: 7.580

5.  Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy.

Authors:  David J Browning; Chong Lee
Journal:  Clin Ophthalmol       Date:  2014-07-25

Review 6.  New concepts in antimalarial use and mode of action in dermatology.

Authors:  Sunil Kalia; Jan P Dutz
Journal:  Dermatol Ther       Date:  2007 Jul-Aug       Impact factor: 2.851

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.